<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:32:40Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7365474" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7365474</identifier>
        <datestamp>2020-07-27</datestamp>
        <setSpec>ploscomp</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS Comput. Biol</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">ploscomp</journal-id>
              <journal-title-group>
                <journal-title>PLoS Computational Biology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1553-734X</issn>
              <issn pub-type="epub">1553-7358</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7365474</article-id>
              <article-id pub-id-type="pmcid">PMC7365474</article-id>
              <article-id pub-id-type="pmc-uid">7365474</article-id>
              <article-id pub-id-type="pmid">32628726</article-id>
              <article-id pub-id-type="pmid">32628726</article-id>
              <article-id pub-id-type="publisher-id">PCOMPBIOL-D-20-00164</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pcbi.1008036</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Diagnostic Medicine</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Mammography</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and Analysis Methods</subject>
                  <subj-group>
                    <subject>Imaging Techniques</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Mammography</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Radiology and Imaging</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Mammography</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Oncology</subject>
                    <subj-group>
                      <subject>Cancers and Neoplasms</subject>
                      <subj-group>
                        <subject>Breast Tumors</subject>
                        <subj-group>
                          <subject>Breast Cancer</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Oncology</subject>
                    <subj-group>
                      <subject>Cancer Treatment</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Diagnostic Medicine</subject>
                    <subj-group>
                      <subject>Cancer Detection and Diagnosis</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Oncology</subject>
                    <subj-group>
                      <subject>Cancer Detection and Diagnosis</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Diagnostic Medicine</subject>
                    <subj-group>
                      <subject>Cancer Detection and Diagnosis</subject>
                      <subj-group>
                        <subject>Cancer Screening</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Oncology</subject>
                    <subj-group>
                      <subject>Cancer Detection and Diagnosis</subject>
                      <subj-group>
                        <subject>Cancer Screening</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Population Biology</subject>
                    <subj-group>
                      <subject>Population Metrics</subject>
                      <subj-group>
                        <subject>Death Rates</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>People and places</subject>
                  <subj-group>
                    <subject>Geographical locations</subject>
                    <subj-group>
                      <subject>Europe</subject>
                      <subj-group>
                        <subject>European Union</subject>
                        <subj-group>
                          <subject>Sweden</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and Analysis Methods</subject>
                  <subj-group>
                    <subject>Mathematical and Statistical Techniques</subject>
                    <subj-group>
                      <subject>Mathematical Models</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Is mammography screening beneficial: An individual-based stochastic model for breast cancer incidence and mortality</article-title>
                <alt-title alt-title-type="running-head">Breast cancer incidence and mortality</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3106-4045</contrib-id>
                  <name>
                    <surname>Le</surname>
                    <given-names>Thuy T. T.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Software</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9022-3157</contrib-id>
                  <name>
                    <surname>Adler</surname>
                    <given-names>Frederick R.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Software</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Department of Mathematics and School of Biological Sciences, University of Utah, Salt Lake City, Utah, United States of America</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor, Michigan, United States of America</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Finley</surname>
                    <given-names>Stacey</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>University of Southern California, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p>The authors have declared that no competing interests exist.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>adler@math.utah.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>7</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>6</day>
                <month>7</month>
                <year>2020</year>
              </pub-date>
              <volume>16</volume>
              <issue>7</issue>
              <elocation-id>e1008036</elocation-id>
              <history>
                <date date-type="received">
                  <day>4</day>
                  <month>2</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>9</day>
                  <month>6</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2020 Le, Adler</copyright-statement>
                <copyright-year>2020</copyright-year>
                <copyright-holder>Le, Adler</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pcbi.1008036.pdf"/>
              <abstract>
                <p>The benefits of mammography screening have been controversial, with conflicting findings from various studies. We hypothesize that unmeasured heterogeneity in tumor aggressiveness underlies these conflicting results. Based on published data from the Canadian National Breast Screening Study (CNBSS), we develop and parameterize an individual-based mechanistic model for breast cancer incidence and mortality that tracks five stages of breast cancer progression and incorporates the effects of age on breast cancer incidence and all-cause mortality. The model accurately reproduces the reported outcomes of the CNBSS. By varying parameters, we predict that the benefits of mammography depend on the effectiveness of cancer treatment and tumor aggressiveness. In particular, patients with the most rapidly growing or potentially largest tumors have the highest benefit and least harm from the screening, with only a relatively small effect of age. However, the model predicts that confining mammography to populations with a high risk of acquiring breast cancer increases the screening benefit only slightly compared with the full population.</p>
              </abstract>
              <abstract abstract-type="summary">
                <title>Author summary</title>
                <p>We developed a mathematical model of breast cancer incidence and mortality in a population based on the CNBSS. All but three of the parameters could be estimated independently from the literature or taken from the CNBSS report, with the remaining ones calibrated to the outcomes of the CNBSS. The model includes three forms of heterogeneity: tumor aggressiveness describing the growth rate, maximum tumor size and age. The treatment response is personalized to a certain extent through dependence of the hazard rate of cancer mortality on tumor aggressiveness and detected tumor size. The model accurately matches the cancer incidence and survival in the CNBSS. We then used the model to quantify the benefit and harm of mammography screening, with benefit measured as the increase in 25-year survival, and harm as the increase in overdiagnosis.</p>
              </abstract>
              <funding-group>
                <funding-statement>This research was partially supported by NIH/NCI U54 grant CA209978 to Andrea Bild, the Modeling the Dynamics fund at the University of Utah, and the University of Utah Department of Mathematics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="8"/>
                <table-count count="3"/>
                <page-count count="16"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>PLOS Publication Stage</meta-name>
                  <meta-value>vor-update-to-uncorrected-proof</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>Publication Update</meta-name>
                  <meta-value>2020-07-16</meta-value>
                </custom-meta>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the manuscript.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the manuscript.</p>
            </notes>
          </front>
          <body>
            <disp-quote>
              <p>This is a <italic>PLOS Computational Biology</italic> Methods paper.</p>
            </disp-quote>
            <sec sec-type="intro" id="sec001">
              <title>Introduction</title>
              <p>Breast cancer is one of three most commonly diagnosed cancers in women, making up 30% of all cancer cases in women in the United States in 2018 [<xref rid="pcbi.1008036.ref001" ref-type="bibr">1</xref>]. Screening mammography was introduced to detect small and more treatable tumors before they cause symptoms. Several trials, such as the Health Insurance Trial [<xref rid="pcbi.1008036.ref002" ref-type="bibr">2</xref>], the Edinburgh randomised trial [<xref rid="pcbi.1008036.ref003" ref-type="bibr">3</xref>, <xref rid="pcbi.1008036.ref004" ref-type="bibr">4</xref>], the Canadian National Breast Screening Study (CNBSS) [<xref rid="pcbi.1008036.ref005" ref-type="bibr">5</xref>] and the Swedish Two-Country Trial [<xref rid="pcbi.1008036.ref006" ref-type="bibr">6</xref>, <xref rid="pcbi.1008036.ref007" ref-type="bibr">7</xref>], have quantified the benefits of screening mammography. The Swedish study and many others reported that breast cancer mortality was significantly reduced due to screening mammography [<xref rid="pcbi.1008036.ref006" ref-type="bibr">6</xref>, <xref rid="pcbi.1008036.ref008" ref-type="bibr">8</xref>], while the CNBSS found no benefits [<xref rid="pcbi.1008036.ref005" ref-type="bibr">5</xref>, <xref rid="pcbi.1008036.ref009" ref-type="bibr">9</xref>]. In addition, Welch <italic>et al</italic>. also found no benefit in their analysis of the SEER data [<xref rid="pcbi.1008036.ref010" ref-type="bibr">10</xref>]. These contradictory conclusions have spurred intense debate over the benefits of screening mammography. The wide implementation of screening mammography has led to an increased rate of small tumor detection and a decreased rate of large tumor detection over the last decades [<xref rid="pcbi.1008036.ref010" ref-type="bibr">10</xref>]. The primary cost of screening is overdiagnosis of small benign or unaggressive tumors that would have remained asymptomatic during a patient’s lifetime, turning a healthy individual into a patient, and requiring follow-up tests and treatments with deleterious side effects including death [<xref rid="pcbi.1008036.ref011" ref-type="bibr">11</xref>]. Overdiagnosis also results in unwanted economic and psychological burdens. To address the controversy, the WISDOM study based on a woman’s individual risk was initiated in the United States in 2016 [<xref rid="pcbi.1008036.ref012" ref-type="bibr">12</xref>].</p>
              <p>Studies based on statistical or stochastic models [<xref rid="pcbi.1008036.ref013" ref-type="bibr">13</xref>–<xref rid="pcbi.1008036.ref015" ref-type="bibr">15</xref>] have quantified the influence of various factors such as age, screening frequency and adherence behavior on the benefits and harmful effects of mammography screening based on different data sources or trials other than the CNBSS. Most of transition probabilities in these models were held constant or age-dependent, and thus did not include the effects of tumor heterogeneity across patients. Using the CNBSS, several analyses ([<xref rid="pcbi.1008036.ref016" ref-type="bibr">16</xref>, <xref rid="pcbi.1008036.ref017" ref-type="bibr">17</xref>] and references therein) have estimated screening sensitivities, transition probabilities and sojourn time distributions. As far as we know, no study has developed a mathematical model to quantify the benefits and harm of screening that explicitly takes tumor heterogeneity into consideration. In this work, we propose a mechanistic model focusing on differences among individuals that provides a mathematical tool to gain insight into breast cancer progression. This model includes all possible transitions of breast cancer before and after detection from cancer incidence and detection through progression, treatment and mortality. Our central focus is on unmeasured heterogeneity, which we include through variation in the aggressiveness of tumor growth and maximum tumor size. By including unaggressive cancers (tumors with small aggressiveness of tumor growth and/or maximum tumor size), we are able to model the role of unmeasured heterogeneity in incidence levels, detected tumor sizes, and long-term outcomes to address the balance between costs and benefits of screening. The benefits are measured as the increase in 25-year survival. The costs are the increase in overdiagnosis quantified in two ways, through the difference in the number of patients diagnosed [<xref rid="pcbi.1008036.ref018" ref-type="bibr">18</xref>], and through the number who would have died due to other causes if treatment were relatively ineffective.</p>
              <p>The proposed model is designed to first reproduce the cancer incidence and mortality in the CNBSS with a minimum of parameter fitting to the data itself [<xref rid="pcbi.1008036.ref005" ref-type="bibr">5</xref>]. By varying key model parameters, we simulate different scenarios of tumor aggressiveness and cancer treatment effectiveness to quantify their effect on the benefit and harm of mammography screening in a population.</p>
              <p>The paper first presents the model framework and describes how parameters were estimated from the literature and the CNBSS. Because of the focus on unmeasured differences in underlying cancers, we term this the Breast Cancer Heterogeneity Aggressiveness Model (BCHAM). Using BCHAM, we experiment with the effectiveness of treatment and the underlying mean and variance of tumor aggressiveness to identify when mammography should provide the greatest benefit and the least harm.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec002">
              <title>Materials and methods</title>
              <sec id="sec003">
                <title>The CNBSS</title>
                <p>The CNBSS has been described in detail [<xref rid="pcbi.1008036.ref005" ref-type="bibr">5</xref>, <xref rid="pcbi.1008036.ref019" ref-type="bibr">19</xref>], and we here summarize its key features (<xref ref-type="fig" rid="pcbi.1008036.g001">Fig 1</xref>). The CNBSS was designed to investigate the benefits of mammography screening in women aged 40–59. The patients were followed up for up to 25 years (22 years on average). A population of 89, 835 healthy women aged 40–59 was randomly assigned to mammography (five annual mammography screens) and control (no mammography). Women in the mammography arm received both annual mammography and physical examination for the first 5 years of follow-up. In the control arm, women aged 40–49 received only a single physical examination at enrollment, and women aged 50–59 received annual physical examination for the first 5 years of follow-up. Participants were considered eligible if they were in good health, had no mammography in the previous 12 months, and had no history of breast cancer. The number of detected breast cancers, breast cancer mortality and all-cause mortality was recorded during the follow-up period.</p>
                <fig id="pcbi.1008036.g001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1008036.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>Flow diagram of the CNBSS [<xref rid="pcbi.1008036.ref019" ref-type="bibr">19</xref>].</title>
                    <p>Values in parentheses indicate the number of individuals in each compartment.</p>
                  </caption>
                  <graphic xlink:href="pcbi.1008036.g001"/>
                </fig>
              </sec>
              <sec id="sec004">
                <title>BCHAM: An individual-based stochastic model</title>
                <p>We use a five-compartment model to track the number of women at each cancer stage via the probabilities and rates of transition between consecutive stages (<xref ref-type="fig" rid="pcbi.1008036.g002">Fig 2</xref>). Let <italic>a</italic> denote the age of a woman at enrollment and <italic>t</italic> the time since the beginning of follow-up. The rate of cancer incidence, <italic>c</italic><sub><italic>a</italic></sub>(<italic>t</italic>), is a bell-shaped function based on the report of Canadian Cancer Registry and Health Statistics Division [<xref rid="pcbi.1008036.ref020" ref-type="bibr">20</xref>]. The rate of non-breast cancer mortality is captured by an exponential function <italic>h</italic><sub><italic>a</italic></sub>(<italic>t</italic>) obtained from the 1991 Canadian statistics reported in [<xref rid="pcbi.1008036.ref021" ref-type="bibr">21</xref>].</p>
                <fig id="pcbi.1008036.g002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1008036.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Diagram of the stages of breast cancer incidence and mortality in BCHAM.</title>
                    <p>Solid arrows indicate transitions from the healthy state, long-dashed arrows from the undetected state, and short-dashed arrows from the detected state.</p>
                  </caption>
                  <graphic xlink:href="pcbi.1008036.g002"/>
                </fig>
                <p>Several models of tumor growth have been used in the literature [<xref rid="pcbi.1008036.ref022" ref-type="bibr">22</xref>, <xref rid="pcbi.1008036.ref023" ref-type="bibr">23</xref>]. We model tumor diameter at time <italic>t</italic> with initial diameter <italic>d</italic><sub>ini</sub> at initial time <italic>t</italic><sub>ini</sub>, <italic>d</italic>(<italic>t</italic>, <italic>t</italic><sub>ini</sub>, <italic>d</italic><sub>ini</sub>, <italic>k</italic>), in <xref rid="pcbi.1008036.t001" ref-type="table">Table 1</xref>, with a Gompertz model of human breast cancer growth [<xref rid="pcbi.1008036.ref022" ref-type="bibr">22</xref>]. The key parameter <italic>k</italic> is the tumor aggressiveness constant. <xref ref-type="fig" rid="pcbi.1008036.g003">Fig 3A</xref> illustrates the effects of tumor aggressiveness <italic>k</italic> and maximum tumor size <italic>d</italic><sub><italic>max</italic></sub> on the Gompertz growth. Detection sensitivities of a tumor are modeled by sigmoid functions [<xref rid="pcbi.1008036.ref024" ref-type="bibr">24</xref>]. <italic>S</italic><sub><italic>m</italic></sub>(<italic>d</italic>), <italic>S</italic><sub><italic>p</italic></sub>(<italic>d</italic>) and <italic>S</italic><sub><italic>s</italic></sub>(<italic>d</italic>) denote the tumor detection sensitivities of mammography, physical screening and self-examination respectively during the follow-up period. To capture undetected cancers entering the study, we let <italic>S</italic><sub><italic>b</italic></sub>(<italic>d</italic>) be the tumor detection sensitivity of self-examination before the beginning of the study to eliminate candidates with noticeable tumors. Mathematical formulas of these functions together with their parameters are provided comprehensively in <xref rid="pcbi.1008036.t001" ref-type="table">Table 1</xref>. Let <italic>t</italic><sub>d</sub> represent the time when a tumor is detected (the time when a patient moves from Stage 2 to 3). Suppose that breast cancers originate from a single cell of the diameter <italic>d</italic><sub>0</sub> at time <italic>t</italic><sub>0</sub>, the time when a woman moves from Stage 1 to 2. Let <italic>d</italic><sub>de</sub> = <italic>d</italic>(<italic>t</italic><sub>d</sub>, <italic>t</italic><sub>0</sub>, <italic>d</italic><sub>0</sub>, <italic>k</italic>) be the size of a tumor at detection time <italic>t</italic><sub>d</sub> &gt; <italic>t</italic><sub>0</sub>. The hazard of cancer mortality depends on the size at detection, tumor aggressiveness and time since detection according to <italic>h</italic>(<italic>d</italic><sub><italic>de</italic></sub>, <italic>k</italic>, <italic>t</italic> − <italic>t</italic><sub><italic>d</italic></sub>) in <xref rid="pcbi.1008036.t001" ref-type="table">Table 1</xref>, which follows a two-parameter Weibull distribution based on the probability of cancer mortality [<xref rid="pcbi.1008036.ref025" ref-type="bibr">25</xref>]. This function includes a parameter <italic>α</italic> that captures the effectiveness of treatment. The effects of <italic>α</italic> and detected tumor size <italic>d</italic><sub><italic>de</italic></sub> on the hazard rate of cancer mortality are depicted in <xref ref-type="fig" rid="pcbi.1008036.g003">Fig 3B</xref>. All parameter values are presented in Tables <xref rid="pcbi.1008036.t001" ref-type="table">1</xref> and <xref rid="pcbi.1008036.t002" ref-type="table">2</xref>.</p>
                <fig id="pcbi.1008036.g003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1008036.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <p>A) Effects of tumor aggressiveness <italic>k</italic> and maximum tumor diameter <italic>d</italic><sub><italic>max</italic></sub> on Gompertz growth. B) Effects of treatment effectiveness <italic>α</italic> and tumor size at detection <italic>d</italic><sub><italic>de</italic></sub> on the hazard rate in a semi-log graph where <italic>k</italic> is kept fixed at 0.1.</p>
                  </caption>
                  <graphic xlink:href="pcbi.1008036.g003"/>
                </fig>
                <table-wrap id="pcbi.1008036.t001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1008036.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Definitions, values and units of model parameters (see also <xref rid="pcbi.1008036.t002" ref-type="table">Table 2</xref>).</title>
                    <p>Citations indicate the source for parameter values, with three parameters estimated from the data as noted.</p>
                  </caption>
                  <alternatives>
                    <graphic id="pcbi.1008036.t001g" xlink:href="pcbi.1008036.t001"/>
                    <table frame="box" rules="all" border="0">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Parameters</th>
                          <th align="center" rowspan="1" colspan="1">Values</th>
                          <th align="center" rowspan="1" colspan="1">Units</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Cancer mortality hazard parameter <italic>Q</italic> [<xref rid="pcbi.1008036.ref026" ref-type="bibr">26</xref>]</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">0.0067</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">1/mm<sup><italic>Z</italic></sup></td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Cancer mortality hazard parameter <italic>Z</italic> (estimated)</td>
                          <td align="left" rowspan="1" colspan="1">1.06</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Cancer mortality hazard parameter <italic>ω</italic> [<xref rid="pcbi.1008036.ref027" ref-type="bibr">27</xref>]</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">1.272</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Scale factor in cancer incidence <italic>γ</italic> (estimated)</td>
                          <td align="left" rowspan="1" colspan="1">1.54</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Maximum tumor diameter ([<xref rid="pcbi.1008036.ref022" ref-type="bibr">22</xref>, <xref rid="pcbi.1008036.ref023" ref-type="bibr">23</xref>]), <italic>d</italic><sub><italic>max</italic></sub></td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">unif(1, 128)<xref ref-type="table-fn" rid="t001fn001"><sup>(1)</sup></xref></td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">mm</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Tumor diameter of a single cell, <italic>d</italic><sub>0</sub></td>
                          <td align="left" rowspan="1" colspan="1">0.0124</td>
                          <td align="left" rowspan="1" colspan="1">mm</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Current tumor diameter at time <italic>t</italic> with an initial diameter <italic>d</italic><sub>0</sub> at time <italic>t</italic><sub>0</sub>, <italic>d</italic>(<italic>t</italic>, <italic>t</italic><sub>0</sub>, <italic>d</italic><sub>0</sub>, <italic>k</italic>) [<xref rid="pcbi.1008036.ref022" ref-type="bibr">22</xref>]</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">
                            <inline-formula id="pcbi.1008036.e001">
                              <alternatives>
                                <graphic id="pcbi.1008036.e001g" xlink:href="pcbi.1008036.e001"/>
                                <mml:math id="M1">
                                  <mml:mstyle displaystyle="true" scriptlevel="0">
                                    <mml:mrow>
                                      <mml:msub>
                                        <mml:mi>d</mml:mi>
                                        <mml:mrow>
                                          <mml:mi>m</mml:mi>
                                          <mml:mi>a</mml:mi>
                                          <mml:mi>x</mml:mi>
                                        </mml:mrow>
                                      </mml:msub>
                                      <mml:msup>
                                        <mml:mrow>
                                          <mml:mo>(</mml:mo>
                                          <mml:mfrac>
                                            <mml:msub>
                                              <mml:mi>d</mml:mi>
                                              <mml:mrow>
                                                <mml:mi>m</mml:mi>
                                                <mml:mi>i</mml:mi>
                                                <mml:mi>n</mml:mi>
                                              </mml:mrow>
                                            </mml:msub>
                                            <mml:msub>
                                              <mml:mi>d</mml:mi>
                                              <mml:mrow>
                                                <mml:mi>m</mml:mi>
                                                <mml:mi>a</mml:mi>
                                                <mml:mi>x</mml:mi>
                                              </mml:mrow>
                                            </mml:msub>
                                          </mml:mfrac>
                                          <mml:mo>)</mml:mo>
                                        </mml:mrow>
                                        <mml:mrow>
                                          <mml:mo form="prefix">exp</mml:mo>
                                          <mml:mo>(</mml:mo>
                                          <mml:mo>-</mml:mo>
                                          <mml:mn>12</mml:mn>
                                          <mml:mi>k</mml:mi>
                                          <mml:mo>(</mml:mo>
                                          <mml:mi>t</mml:mi>
                                          <mml:mo>-</mml:mo>
                                          <mml:msub>
                                            <mml:mi>t</mml:mi>
                                            <mml:mn>0</mml:mn>
                                          </mml:msub>
                                          <mml:mo>)</mml:mo>
                                          <mml:mo>)</mml:mo>
                                        </mml:mrow>
                                      </mml:msup>
                                    </mml:mrow>
                                  </mml:mstyle>
                                </mml:math>
                              </alternatives>
                            </inline-formula>
                          </td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">mm</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Tumor aggressiveness, <italic>k</italic> [<xref rid="pcbi.1008036.ref022" ref-type="bibr">22</xref>]</td>
                          <td align="left" rowspan="1" colspan="1">
                            <inline-formula id="pcbi.1008036.e002">
                              <alternatives>
                                <graphic id="pcbi.1008036.e002g" xlink:href="pcbi.1008036.e002"/>
                                <mml:math id="M2">
                                  <mml:mrow>
                                    <mml:mo form="prefix">log</mml:mo>
                                    <mml:mrow>
                                      <mml:mo>(</mml:mo>
                                      <mml:mi>k</mml:mi>
                                      <mml:mo>)</mml:mo>
                                    </mml:mrow>
                                    <mml:mo>∈</mml:mo>
                                    <mml:mi mathvariant="script">N</mml:mi>
                                    <mml:mrow>
                                      <mml:mo>(</mml:mo>
                                      <mml:msub>
                                        <mml:mi>μ</mml:mi>
                                        <mml:mi>k</mml:mi>
                                      </mml:msub>
                                      <mml:mo>,</mml:mo>
                                      <mml:msub>
                                        <mml:mi>σ</mml:mi>
                                        <mml:mi>k</mml:mi>
                                      </mml:msub>
                                      <mml:mo>)</mml:mo>
                                    </mml:mrow>
                                  </mml:mrow>
                                </mml:math>
                              </alternatives>
                            </inline-formula>
                          </td>
                          <td align="left" rowspan="1" colspan="1">month<sup>−1</sup></td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Cancer incidence parameters <italic>μ</italic><sub>age</sub>, <italic>σ</italic><sub>age</sub> [<xref rid="pcbi.1008036.ref020" ref-type="bibr">20</xref>]</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">76.86, 19.5</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">years old</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">True cancer incidence rate, <italic>c</italic><sub><italic>a</italic></sub>(<italic>t</italic>) [<xref rid="pcbi.1008036.ref020" ref-type="bibr">20</xref>]</td>
                          <td align="left" rowspan="1" colspan="1">
                            <inline-formula id="pcbi.1008036.e003">
                              <alternatives>
                                <graphic id="pcbi.1008036.e003g" xlink:href="pcbi.1008036.e003"/>
                                <mml:math id="M3">
                                  <mml:mstyle displaystyle="true" scriptlevel="0">
                                    <mml:mrow>
                                      <mml:mfrac>
                                        <mml:mrow>
                                          <mml:mn>0</mml:mn>
                                          <mml:mo>.</mml:mo>
                                          <mml:mn>1967</mml:mn>
                                          <mml:mspace width="0.166667em"/>
                                          <mml:mi>γ</mml:mi>
                                        </mml:mrow>
                                        <mml:mrow>
                                          <mml:msub>
                                            <mml:mi>σ</mml:mi>
                                            <mml:mtext>age</mml:mtext>
                                          </mml:msub>
                                          <mml:msqrt>
                                            <mml:mrow>
                                              <mml:mn>2</mml:mn>
                                              <mml:mi>π</mml:mi>
                                            </mml:mrow>
                                          </mml:msqrt>
                                        </mml:mrow>
                                      </mml:mfrac>
                                      <mml:mo form="prefix">exp</mml:mo>
                                      <mml:mo>(</mml:mo>
                                      <mml:mfrac>
                                        <mml:mrow>
                                          <mml:mo>-</mml:mo>
                                          <mml:msup>
                                            <mml:mrow>
                                              <mml:mo>(</mml:mo>
                                              <mml:mi>t</mml:mi>
                                              <mml:mo>+</mml:mo>
                                              <mml:mi>a</mml:mi>
                                              <mml:mo>-</mml:mo>
                                              <mml:msub>
                                                <mml:mi>μ</mml:mi>
                                                <mml:mtext>age</mml:mtext>
                                              </mml:msub>
                                              <mml:mo>)</mml:mo>
                                            </mml:mrow>
                                            <mml:mn>2</mml:mn>
                                          </mml:msup>
                                        </mml:mrow>
                                        <mml:mrow>
                                          <mml:mn>2</mml:mn>
                                          <mml:msubsup>
                                            <mml:mi>σ</mml:mi>
                                            <mml:mrow>
                                              <mml:mtext>age</mml:mtext>
                                            </mml:mrow>
                                            <mml:mn>2</mml:mn>
                                          </mml:msubsup>
                                        </mml:mrow>
                                      </mml:mfrac>
                                      <mml:mo>)</mml:mo>
                                    </mml:mrow>
                                  </mml:mstyle>
                                </mml:math>
                              </alternatives>
                            </inline-formula>
                            <xref ref-type="table-fn" rid="t001fn002">
                              <sup>(2)</sup>
                            </xref>
                          </td>
                          <td align="left" rowspan="1" colspan="1">year<sup>−1</sup></td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Rate of other cause mortality, <italic>h</italic><sub><italic>a</italic></sub>(<italic>t</italic>) [<xref rid="pcbi.1008036.ref021" ref-type="bibr">21</xref>]</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">0.208 × 10<sup>−5</sup>exp(0.1196(<italic>t</italic> + <italic>a</italic>))</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">year<sup>−1</sup></td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Detection sensitivity of a tumor size <italic>d</italic>, <italic>S</italic><sub><italic>j</italic></sub>(<italic>d</italic>), <italic>j</italic> ∈ {<italic>b</italic>, <italic>m</italic>, <italic>p</italic>, <italic>s</italic>}, [<xref rid="pcbi.1008036.ref028" ref-type="bibr">28</xref>]</td>
                          <td align="left" rowspan="1" colspan="1">
                            <inline-formula id="pcbi.1008036.e004">
                              <alternatives>
                                <graphic id="pcbi.1008036.e004g" xlink:href="pcbi.1008036.e004"/>
                                <mml:math id="M4">
                                  <mml:mstyle displaystyle="true" scriptlevel="0">
                                    <mml:mfrac>
                                      <mml:mrow>
                                        <mml:mo form="prefix">exp</mml:mo>
                                        <mml:mo>(</mml:mo>
                                        <mml:mrow>
                                          <mml:mo>(</mml:mo>
                                          <mml:mi>d</mml:mi>
                                          <mml:mo>-</mml:mo>
                                          <mml:msub>
                                            <mml:mi>b</mml:mi>
                                            <mml:mrow>
                                              <mml:mi>j</mml:mi>
                                              <mml:mn>2</mml:mn>
                                            </mml:mrow>
                                          </mml:msub>
                                          <mml:mo>)</mml:mo>
                                        </mml:mrow>
                                        <mml:mo>/</mml:mo>
                                        <mml:msub>
                                          <mml:mi>b</mml:mi>
                                          <mml:mn>1</mml:mn>
                                        </mml:msub>
                                        <mml:mo>)</mml:mo>
                                      </mml:mrow>
                                      <mml:mrow>
                                        <mml:mn>1</mml:mn>
                                        <mml:mo>+</mml:mo>
                                        <mml:mo form="prefix">exp</mml:mo>
                                        <mml:mo>(</mml:mo>
                                        <mml:mrow>
                                          <mml:mo>(</mml:mo>
                                          <mml:mi>d</mml:mi>
                                          <mml:mo>-</mml:mo>
                                          <mml:msub>
                                            <mml:mi>b</mml:mi>
                                            <mml:mrow>
                                              <mml:mi>j</mml:mi>
                                              <mml:mn>2</mml:mn>
                                            </mml:mrow>
                                          </mml:msub>
                                          <mml:mo>)</mml:mo>
                                        </mml:mrow>
                                        <mml:mo>/</mml:mo>
                                        <mml:msub>
                                          <mml:mi>b</mml:mi>
                                          <mml:mn>1</mml:mn>
                                        </mml:msub>
                                        <mml:mo>)</mml:mo>
                                      </mml:mrow>
                                    </mml:mfrac>
                                  </mml:mstyle>
                                </mml:math>
                              </alternatives>
                            </inline-formula>
                          </td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Detection sensitivity constants <italic>b</italic><sub>1</sub>, <italic>b</italic><sub><italic>m</italic>2</sub>, <italic>b</italic><sub><italic>p</italic>2</sub>, <italic>b</italic><sub><italic>s</italic>2</sub> [<xref rid="pcbi.1008036.ref019" ref-type="bibr">19</xref>, <xref rid="pcbi.1008036.ref028" ref-type="bibr">28</xref>]</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">1.5, 6.33, 18.5, 20</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">mm</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Detection sensitivity constant <italic>b</italic><sub><italic>b</italic>2</sub> (estimated)</td>
                          <td align="left" rowspan="1" colspan="1">40</td>
                          <td align="left" rowspan="1" colspan="1">mm</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Hazard rate of cancer mortality <italic>h</italic>(<italic>d</italic><sub><italic>de</italic></sub>, <italic>k</italic>, <italic>t</italic>), based on [<xref rid="pcbi.1008036.ref026" ref-type="bibr">26</xref>, <xref rid="pcbi.1008036.ref027" ref-type="bibr">27</xref>]</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1"><inline-formula id="pcbi.1008036.e005"><alternatives><graphic id="pcbi.1008036.e005g" xlink:href="pcbi.1008036.e005"/><mml:math id="M5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>k</mml:mi><mml:mi>α</mml:mi></mml:msup><mml:msubsup><mml:mi>d</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mi>Z</mml:mi></mml:msubsup><mml:mi>ω</mml:mi><mml:msup><mml:mi>t</mml:mi><mml:mrow><mml:mi>ω</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1008036.e006"><alternatives><graphic id="pcbi.1008036.e006g" xlink:href="pcbi.1008036.e006"/><mml:math id="M6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo form="prefix">log</mml:mo><mml:mo>(</mml:mo><mml:mi>Q</mml:mi><mml:mo>/</mml:mo><mml:msup><mml:mn>15</mml:mn><mml:mi>ω</mml:mi></mml:msup><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo form="prefix">log</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>3</mml:mn><mml:mo>.</mml:mo><mml:mn>19</mml:mn></mml:mrow></mml:mstyle></mml:math></alternatives></inline-formula></td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Mean of log(<italic>k</italic>) adapted from [<xref rid="pcbi.1008036.ref022" ref-type="bibr">22</xref>], <italic>μ</italic><sub><italic>k</italic></sub></td>
                          <td align="left" rowspan="1" colspan="1">−2.9</td>
                          <td align="left" rowspan="1" colspan="1">month<sup>−1</sup></td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Standard deviation of log(<italic>k</italic>) [<xref rid="pcbi.1008036.ref022" ref-type="bibr">22</xref>], <italic>σ</italic><sub><italic>k</italic></sub></td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">0.71</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">month<sup>−1</sup></td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Mean of <italic>k</italic>, <italic>k</italic><sub><italic>m</italic></sub></td>
                          <td align="left" rowspan="1" colspan="1">
                            <inline-formula id="pcbi.1008036.e007">
                              <alternatives>
                                <graphic id="pcbi.1008036.e007g" xlink:href="pcbi.1008036.e007"/>
                                <mml:math id="M7">
                                  <mml:mrow>
                                    <mml:mo form="prefix">exp</mml:mo>
                                    <mml:mo>(</mml:mo>
                                    <mml:msub>
                                      <mml:mi>μ</mml:mi>
                                      <mml:mi>k</mml:mi>
                                    </mml:msub>
                                    <mml:mo>+</mml:mo>
                                    <mml:msubsup>
                                      <mml:mi>σ</mml:mi>
                                      <mml:mi>k</mml:mi>
                                      <mml:mn>2</mml:mn>
                                    </mml:msubsup>
                                    <mml:mo>/</mml:mo>
                                    <mml:mn>2</mml:mn>
                                    <mml:mo>)</mml:mo>
                                    <mml:mo>=</mml:mo>
                                    <mml:mn>0</mml:mn>
                                    <mml:mo>.</mml:mo>
                                    <mml:mn>0708</mml:mn>
                                  </mml:mrow>
                                </mml:math>
                              </alternatives>
                            </inline-formula>
                          </td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p><sup>(1)</sup> unif(1, 128) is a uniform distribution on the interval [1, 128].</p>
                    </fn>
                    <fn id="t001fn002">
                      <p><sup>(2)</sup> A polynomial approximation of <italic>c</italic><sub><italic>a</italic></sub>(<italic>t</italic>) was used in programming to speed up model simulations.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap id="pcbi.1008036.t002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1008036.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Study-specific values of BCHAM parameters based on the design of the CNBSS [<xref rid="pcbi.1008036.ref005" ref-type="bibr">5</xref>, <xref rid="pcbi.1008036.ref023" ref-type="bibr">23</xref>].</title>
                  </caption>
                  <alternatives>
                    <graphic id="pcbi.1008036.t002g" xlink:href="pcbi.1008036.t002"/>
                    <table frame="box" rules="all" border="0">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Parameters</th>
                          <th align="left" rowspan="1" colspan="1">Values</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Age of participants, <italic>a</italic></td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">unif(40, 59)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Average follow-up time, <italic>t</italic></td>
                          <td align="left" rowspan="1" colspan="1">0–22</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Population size, <italic>N</italic><sub>0</sub></td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">see <xref ref-type="fig" rid="pcbi.1008036.g001">Fig 1</xref></td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Mammography screening schedule for women aged 40–59 in the mammography arm, <italic>T</italic><sub>m</sub></td>
                          <td align="left" rowspan="1" colspan="1">{0<sup>th</sup>, 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup>, 4<sup>th</sup>}</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Physical examination schedule for women aged 40–59 in the mammography arm, <italic>T</italic><sub>p</sub></td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">{0<sup>th</sup>, 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup>, 4<sup>th</sup>}</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Physical examination schedule for women aged 40–49, <italic>T</italic><sub>p</sub> in the control arm</td>
                          <td align="left" rowspan="1" colspan="1">{0<sup>th</sup>}</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Physical examination schedule for women aged 50–59, <italic>T</italic><sub>p</sub> in the control arm</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">{0<sup>th</sup>, 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup>, 4<sup>th</sup>}</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
                <p>At enrollment, the participants can be in either the healthy or the undetected cancer compartment. As time passes, they can transfer between stages (<xref ref-type="fig" rid="pcbi.1008036.g002">Fig 2</xref>).</p>
                <list list-type="simple">
                  <list-item>
                    <label>Stage 1</label>
                    <p>An individual in the healthy compartment may develop undetected breast cancer at a rate <italic>c</italic><sub><italic>a</italic></sub>(<italic>t</italic>) or die due to other causes apart from breast cancer at a rate <italic>h</italic><sub><italic>a</italic></sub>(<italic>t</italic>) (solid arrows in <xref ref-type="fig" rid="pcbi.1008036.g002">Fig 2</xref>).</p>
                  </list-item>
                  <list-item>
                    <label>Stage 2</label>
                    <p>During follow-up, an individual with undetected cancer can be detected with a probability of <italic>S</italic><sub><italic>j</italic></sub>(<italic>d</italic>), <italic>j</italic> ∈ {<italic>m</italic>, <italic>p</italic>, <italic>s</italic>}, or die of other causes at a rate of <italic>h</italic><sub><italic>a</italic></sub>(<italic>t</italic>) (long-dashed arrows in <xref ref-type="fig" rid="pcbi.1008036.g002">Fig 2</xref>).</p>
                  </list-item>
                  <list-item>
                    <label>Stage 3</label>
                    <p>An individual with detected cancer may die of breast cancer at a rate of <italic>h</italic>(<italic>d</italic><sub><italic>de</italic></sub>, <italic>k</italic>, <italic>t</italic> − <italic>t</italic><sub><italic>d</italic></sub>) or of other causes at rate <italic>h</italic><sub><italic>a</italic></sub>(<italic>t</italic>) (short-dashed arrows in <xref ref-type="fig" rid="pcbi.1008036.g002">Fig 2</xref>).</p>
                  </list-item>
                </list>
                <p>Here we assume that once an individual gets diagnosed, they will be labeled as detected cancer for the rest of their life regardless of survival status, which results in no individuals moving from Stage 3 to Stage 1. Furthermore, it should be noted that tumor aggressiveness <italic>k</italic>, <italic>d</italic><sub><italic>max</italic></sub> and age are incorporated as individualized factors. We simulate a population of <italic>N</italic><sub>0</sub> individuals. The total women in the <italic>i</italic>-th compartment at time <italic>t</italic> is <inline-formula id="pcbi.1008036.e008"><alternatives><graphic xlink:href="pcbi.1008036.e008.jpg" id="pcbi.1008036.e008g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M8"><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:msubsup><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> where <inline-formula id="pcbi.1008036.e009"><alternatives><graphic xlink:href="pcbi.1008036.e009.jpg" id="pcbi.1008036.e009g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M9"><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mspace width="0.166667em"/><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>,</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> is an indicator function of the stage <italic>i</italic> of an individual <italic>k</italic> at time <italic>t</italic>.</p>
              </sec>
              <sec id="sec005">
                <title>Parameter calibration based on the CNBSS</title>
                <p>We simulate the model using the CNBSS [<xref rid="pcbi.1008036.ref005" ref-type="bibr">5</xref>] to calibrate model parameters that cannot be estimated independently from the literature. In the CNBSS, the large number of breast cancers detected during the first year of follow-up (253 and 170 diagnosed cancers in the mammography and control arms respectively (Table 1 in [<xref rid="pcbi.1008036.ref005" ref-type="bibr">5</xref>])) suggests that at enrollment the participants may have been either in the healthy or undetected cancer compartment. To capture this, we began each simulated patient as healthy 6 years prior to the study initiation, with 6 years as a sufficient time period for previously originating cancers to be diagnosed before the first year of the study. In accordance with the study design, we assume that cancers can be diagnosed only by self physical examination with the detection sensitivity <italic>S</italic><sub><italic>b</italic></sub>(<italic>d</italic>) before the study. Patients who get diagnosed, die of breast cancer or of other causes before the beginning of the study are not included in the simulated population. A time step of 1 day is chosen for numerical simulation. Due to the nature of discretization, possibilities of two events occurring during a period of a time step are encompassed in our numerical simulations. In particular, Algorithm I in [<xref rid="pcbi.1008036.ref029" ref-type="bibr">29</xref>] was used to speed up the simulation of Stage 1 and also eliminate the simultaneous occurrence of undetected cancer and non-breast cancer death events. Because implementation of Algorithm I requires the integration of the cancer incidence rate <italic>c</italic><sub><italic>a</italic></sub>(<italic>t</italic>), we used a polynomial approximation of <italic>c</italic><sub><italic>a</italic></sub>(<italic>t</italic>). Moreover, we considered all possible cases including the concurrence of detected cancer and non-breast cancer death events when simulating Stage 2. At any time during the follow-up, if the death event occurs, the simulation is terminated.</p>
                <p>Let <italic>X</italic><sub><italic>i</italic></sub> be the simulated outcomes, the number of detected cancers and the number of cancer deaths, and <italic>Y</italic><sub><italic>i</italic></sub> be the corresponding recorded observations from the study. For the <italic>j</italic>th realization of our model, <italic>S</italic><sub><italic>j</italic></sub> is the sum of squared deviations, i.e. <italic>S</italic><sub><italic>j</italic></sub> = ∑<sub><italic>i</italic></sub>(<italic>X</italic><sub><italic>i</italic></sub> − <italic>Y</italic><sub><italic>i</italic></sub>)<sup>2</sup>. The three unknown parameters (detection sensitivity constant <italic>b</italic><sub><italic>b</italic>2</sub>, scale factor in cancer incidence <italic>γ</italic> and cancer mortality hazard parameter <italic>Z</italic>) are chosen to minimize the expected value of <italic>S</italic>. Model calibration is carried out using the data only from the control arm. Then we simulate the model with the estimated parameters over both arms to reproduce the outcomes of the CNBSS.</p>
              </sec>
              <sec id="sec006">
                <title>Statistics and calculation of overdiagnosis</title>
                <p>To quantify the survival and overdiagnosis, we simulated each patient in the BCHAM 100 times, 50 times in the mammography and 50 in the control arm, with identical parameters and time of onset of cancer. We used Cox proportional hazards (the coxph function in R [<xref rid="pcbi.1008036.ref030" ref-type="bibr">30</xref>]) to evaluate the effect of mammography arm on survival from the time of acquiring cancer, thus avoiding the effects of lead time bias [<xref rid="pcbi.1008036.ref018" ref-type="bibr">18</xref>]. To illustrate the effects, we conduct these regressions on data broken up into sextiles of aggressiveness <italic>k</italic> and maximum tumor diameter <italic>d</italic><sub><italic>max</italic></sub>, and by the time of cancer acquisition before, during or after the study. We term these 108 groups as study subcohorts. To estimate confidence limits, we bootstrap the simulated patients by sampling with replacement.</p>
                <p>We quantify the number of diagnoses by computing the number of patients diagnosed in each arm and comparing in each subcohort with a <italic>χ</italic><sup>2</sup> test. To test for overdiagnosis itself, we compute the probability of death from other causes before death from cancer using the hazards <italic>h</italic> and <italic>h</italic><sub><italic>a</italic></sub> from <xref rid="pcbi.1008036.t001" ref-type="table">Table 1</xref> and integrating as in [<xref rid="pcbi.1008036.ref031" ref-type="bibr">31</xref>]. To minimize confounding the benefits of treatment that sufficiently delay cancer-induced mortality to allow death from other causes, we lower the treatment effectiveness parameter in the cancer mortality hazard <italic>h</italic> to its minimum value <italic>α</italic> = 2.5.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec007">
              <title>Results</title>
              <sec id="sec008">
                <title>Fit with CNBSS results</title>
                <p>The outcomes of the CNBSS were used to calibrate our model parameters. Only three unknown parameters (<italic>b</italic><sub><italic>b</italic>2</sub>, <italic>γ</italic> and <italic>Z</italic>) were estimated using the data from the control arm. The model was then simulated with the fitted parameters over both arms to reproduce the outcomes of the CNBSS, which fall in the range of our model projections (more than half within the first and third quartiles, Figs <xref ref-type="fig" rid="pcbi.1008036.g004">4</xref> and <xref ref-type="fig" rid="pcbi.1008036.g005">5</xref> and <xref rid="pcbi.1008036.t003" ref-type="table">Table 3</xref>). Those simulation results include the number of detected cancers, deaths from cancer, deaths from other causes, and the distributions of age at diagnosis in both arms. With this minimal calibration, the BCHAM is still able to capture well the outcomes of the CNBSS.</p>
                <fig id="pcbi.1008036.g004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1008036.g004</object-id>
                  <label>Fig 4</label>
                  <caption>
                    <title>The number of simulated (box-plots) versus recorded (red square, CNBSS) breast cancers diagnosed and deaths from breast cancer in mammography arm (MA) and control arm (CA).</title>
                  </caption>
                  <graphic xlink:href="pcbi.1008036.g004"/>
                </fig>
                <fig id="pcbi.1008036.g005" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1008036.g005</object-id>
                  <label>Fig 5</label>
                  <caption>
                    <title>Simulated (box-plots) versus recorded (red square, CNBSS) number of breast cancers diagnosed in mammography arm (MA) and control arm (CA) by study year.</title>
                  </caption>
                  <graphic xlink:href="pcbi.1008036.g005"/>
                </fig>
                <table-wrap id="pcbi.1008036.t003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1008036.t003</object-id>
                  <label>Table 3</label>
                  <caption>
                    <title>Comparison of simulated versus recorded ages at diagnosis (at cancer death in 25 years) for breast cancer detecting during screening phase (from the beginning of follow-up to the 5<sup>th</sup> year) in mammography arm versus control arm.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pcbi.1008036.t003g" xlink:href="pcbi.1008036.t003"/>
                    <table frame="box" rules="all" border="0">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1">Mean</th>
                          <th align="left" rowspan="1" colspan="1">Range</th>
                        </tr>
                        <tr>
                          <th align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1"/>
                          <th align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Simulated (recorded)</th>
                          <th align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Simulated (recorded)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Age at diagnosis (years):</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">In mammography arm</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">53.08(52.5)</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">40.00–63.84(40–64)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">In control arm</td>
                          <td align="left" rowspan="1" colspan="1">53.44(52.6)</td>
                          <td align="left" rowspan="1" colspan="1">40.02–63.82(40–64)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">Age at cancer death (years):</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">In mammography arm</td>
                          <td align="left" rowspan="1" colspan="1">60.97(59.9)</td>
                          <td align="left" rowspan="1" colspan="1">40.56–80.76(43–80)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">In control arm</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">60.70(60.6)</td>
                          <td align="left" style="background-color:#E6E6E6" rowspan="1" colspan="1">41.43–80.30(43–83)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
              </sec>
              <sec id="sec009">
                <title>Benefit and harm of mammography screening</title>
                <p>The accurate fit of the model to the data under current conditions motivates testing how various model parameters affect the balance between benefit and harm. We first quantify the benefit of increasing the parameter <italic>α</italic> that describes the effectiveness of treatment (<xref ref-type="fig" rid="pcbi.1008036.g006">Fig 6</xref>). Value of screening is estimated as the percent increase in survival after 25 years of follow-up. As can be seen, when cancer treatment is highly effective, mammography screening provides only a minimal benefit.</p>
                <fig id="pcbi.1008036.g006" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1008036.g006</object-id>
                  <label>Fig 6</label>
                  <caption>
                    <title>Survivorship as a function of the treatment effectiveness parameter <italic>α</italic>.</title>
                  </caption>
                  <graphic xlink:href="pcbi.1008036.g006"/>
                </fig>
                <p>To compare the benefit and harm as a function of age, tumor aggressiveness <italic>k</italic>, and maximum tumor diameter <italic>d</italic><sub><italic>max</italic></sub>, we simulate identical populations in both arms. In the simulation, participants receive an annual mammography and physical examinations in the mammography arm, or only an annual physical examination in the control for the first five years of follow-up. The simulation of each patient was repeated 50 times to reduce variance due to individual variation. Higher values of <italic>k</italic> and <italic>d</italic><sub><italic>max</italic></sub> strongly increase survival benefit from mammography screening, and decrease overdiagnosis since a tumor with large <italic>k</italic> and <italic>d</italic><sub><italic>max</italic></sub> is more likely (if not surely) to be malignant and a patient with this kind of tumor is less likely to be overdiagnosed (<xref ref-type="fig" rid="pcbi.1008036.g007">Fig 7A</xref>). The effects of age are much weaker, with slightly improved benefits in the middle age groups (women between the ages of 44 and 56). For patients with unaggressive tumors (small values of <italic>k</italic> and/or <italic>d</italic><sub><italic>max</italic></sub>), mammography provides little benefit and the highest harm. Our CNBSS-calibrated model estimates that the maximum benefit of mammography screening is about 1.2% increase in 25-year survival shown in <xref ref-type="fig" rid="pcbi.1008036.g007">Fig 7A</xref>. This insignificant quantity is consistent with the empirical data of the CNBSS which has shown no screening benefit. The magnitudes of the benefit and harm strongly depend on the study to which the model parameters are fitted.</p>
                <fig id="pcbi.1008036.g007" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1008036.g007</object-id>
                  <label>Fig 7</label>
                  <caption>
                    <title>Benefit (increase in probability of surviving patients after 25 years of follow-up) and harm (increase in probability of patients diagnosed with cancers that would not have been the cause of death) of mammography screening.</title>
                    <p>Size of dots indicates age, the size increases with age. Color saturation increases with value of <italic>d</italic><sub><italic>max</italic></sub>. Markers indicate value of <italic>k</italic>, triangle (square) corresponds to the smallest (largest) value of <italic>k</italic>. A) The baseline case, and B) the high risk case with an increase of breast cancer incidence by a factor of 5 in comparison with the baseline case presented.</p>
                  </caption>
                  <graphic xlink:href="pcbi.1008036.g007"/>
                </fig>
                <p>We also illustrate overdiagnosis and survivorship as functions of whether patients first acquired their cancer before, during, or after the study, and of the aggressiveness (<italic>k</italic>) and the maximum tumor diameter <italic>d</italic><sub><italic>max</italic></sub> of their tumor. For overdiagnosis (<xref ref-type="fig" rid="pcbi.1008036.g008">Fig 8A and 8B</xref>), we compare the difference in the number of patients per thousand diagnosed in the mammography and control arms (top number) with the difference in the number of patients per thousand who would have died of other causes with less effective treatment (<italic>α</italic> = 2.5, bottom number). For survivorship (<xref ref-type="fig" rid="pcbi.1008036.g008">Fig 8C and 8D</xref>), we compare the difference in number of deaths per thousand in the mammography and control arms (top number) with the hazard ratio of death due to inclusion in the mammography arm (bottom number).</p>
                <fig id="pcbi.1008036.g008" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1008036.g008</object-id>
                  <label>Fig 8</label>
                  <caption>
                    <title>Comparison of simulated mammography and control arms after bootstrap analysis.</title>
                    <p>The aggressiveness class indicates the value of the tumor aggressiveness parameter <italic>k</italic> (1 represents <italic>k</italic> &lt; 0.0275, 2 from 0.0275–0.0400, 3 from 0.040–0.0543, 4 from 0.0543–0.0726, 5 from 0.0726–0.104 and 6 values greater than 0.104). The maximum tumor diameter class indicates the parameter <italic>d</italic><sub><italic>max</italic></sub>, with all values in mm (1 represents <italic>d</italic><sub><italic>max</italic></sub> &lt; 22.36, 2 from 22.36–43.36, 3 from 43.36–64.16, 4 from 64.16–85.05, 5 from 85.05–106.4 and 6 values greater than 106.4). Ranges are from 500 bootstrap replicates of the simulated data. Panels A) and B) show the difference in the number of patients per thousand diagnosed (top number) and the difference in the number per thousand who would have died first of other causes with ineffective treatment (bottom number, <italic>α</italic> = 2.5). Colors indicate the significance of the difference in probability of diagnosis in the two arms (red for higher in mammography arm, green for lower). Panels C) and D) show the difference in the number of patients per thousand who died of any cause (top number) and the hazard ratio associated with mammography (bottom number) and colors indicate the significance of the effect of mammography on survival (red for higher hazard in the mammography arm, green for lower).</p>
                  </caption>
                  <graphic xlink:href="pcbi.1008036.g008"/>
                </fig>
                <p>For patients who acquired an undetected tumor before the beginning of the study, those with ultimately small tumors are highly overdiagnosed and experience reduced survival due to the effects of the treatment. The greatest survival benefits accrue to patients with largest and most aggressive tumors. Patients who acquire a tumor during the five years of the study show a similar but weaker pattern of overdiagnosis, and no strong survival cost of overtreatment of rapidly-growing but ultimately small tumors. Patients who acquired tumors after the conclusion of the study show no effect of mammography as expected. These observations suggest that overdiagnosis mainly occurs at the first screening [<xref rid="pcbi.1008036.ref032" ref-type="bibr">32</xref>].</p>
                <p>To capture a high-risk population, such as women with germline BRCA1 and BRCA2 mutations, family breast cancer history, hormone therapy and smoking history, we assume an increase of breast cancer incidence by a factor of 5 [<xref rid="pcbi.1008036.ref033" ref-type="bibr">33</xref>] over the baseline case. The main observations remain largely unchanged. In a high risk population, mammography screening is slightly more beneficial for younger women, illustrated by a slight shift in the age effect in <xref ref-type="fig" rid="pcbi.1008036.g007">Fig 7B</xref> compared with <xref ref-type="fig" rid="pcbi.1008036.g007">Fig 7A</xref>.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec010">
              <title>Discussion</title>
              <p>We have developed an individual-based mechanistic model of breast cancer incidence and mortality in a population based on the Canadian National Breast Screening Study (CNBSS). All but three of the parameters could be estimated independently from the literature or taken from the CNBSS report, with the remaining ones calibrated to the outcomes of the CNBSS. The model includes three forms of heterogeneity: tumor aggressiveness describing the growth rate, maximum tumor size and age. The treatment response is personalized to a certain extent through dependence of the hazard rate of cancer mortality on tumor aggressiveness and detected tumor size. We did not include more specific differences in response to therapy, such as through pre-existing resistance, due to lack of sufficient information.</p>
              <p>The model accurately matches the cancer incidence and survival in the CNBSS (see the <xref ref-type="sec" rid="sec007">Results</xref> section). We then use the model to quantify the benefit and harm of mammography screening, with benefit measured as the increase in 25-year survival, and harm as the increase in overdiagnosis. The benefit of screening decreases almost to zero with highly effective treatment. In general, patients with the most rapidly growing or potentially largest tumors have the highest benefit and least harm from mammography screening, with only a relatively small effect of age.</p>
              <p>We measured overdiagnosis in two ways, through the difference in the number of patients diagnosed (excess incidence [<xref rid="pcbi.1008036.ref018" ref-type="bibr">18</xref>]), and through the number who would have died of other causes if treatment were relatively ineffective. The goal of treatment is, of course, to ensure that all patients have the chance to die of something else, and thus comparing the number of deaths with relatively effective treatment confounds true overdiagnosis with successful treatment. An alternative defines overdiagnosis as cancers that would not have presented clinically during the patient’s lifetime [<xref rid="pcbi.1008036.ref015" ref-type="bibr">15</xref>, <xref rid="pcbi.1008036.ref031" ref-type="bibr">31</xref>] which is most appropriate for modeling studies that optimize timing and type of testing.</p>
              <p>Unlike age or other known risk factors, it is difficult in practice to predict specific tumor characteristics in an individual patient before recommending screening. In addition to improving mammography technology, increasing the net benefit of screening may require pretreatment tests that can identify women at the greatest risk of the highly aggressive cancers.</p>
              <p>The CNBSS has been criticized because participants were volunteers [<xref rid="pcbi.1008036.ref034" ref-type="bibr">34</xref>] and thus possibly at higher risk than the general population. However, because participants were then randomized, this selection of volunteers should only increase the effect size of screening, but not create a change in direction.</p>
              <p>The developed model has several limitations. The parameters from the literature come from a variety of sources and studies that might not apply across all populations. The remaining three are based on a single study, and future work will test how effectively it can reproduce the outcome of other clinical trials, especially the Swedish trial [<xref rid="pcbi.1008036.ref006" ref-type="bibr">6</xref>, <xref rid="pcbi.1008036.ref007" ref-type="bibr">7</xref>], by modifying few or no parameter values. Calibrating this model to the Swedish trial, we hope to comprehend which factors contribute to the contradicting outcomes of these two studies. In addition, our modeling of treatment is quite simplified, without taking into account recent improvements or different treatments for different breast cancer types.</p>
              <p>Our model brings a new quantitative tool to bear on the controversy over the use of mammography screening. This CNBSS-based model suggests, in line with recent trials, that the benefits are sufficiently small and the harm sufficiently large to make screening of dubious value except in patients destined to have highly aggressive cancers, who of course are difficult if not impossible to identify in advance.</p>
            </sec>
          </body>
          <back>
            <ack>
              <p>We thank Dr. Adam Cohen for useful comments on an earlier draft, the members of sLaM for discussion and the anonymous reviewers for their comments and suggestions.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pcbi.1008036.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Siegel</surname><given-names>RL</given-names></name>, <name><surname>Miller</surname><given-names>KD</given-names></name>, <name><surname>Jemal</surname><given-names>A</given-names></name>. <article-title>Cancer statistics, 2018</article-title>. <source>CA: A Cancer Journal for Clinicians</source>. <year>2018</year>;<volume>68</volume>(<issue>1</issue>):<fpage>7</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">29313949</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Shapiro</surname><given-names>S</given-names></name>, <name><surname>Strax</surname><given-names>P</given-names></name>, <name><surname>Venet</surname><given-names>L</given-names></name>. <article-title>Periodic breast cancer screening in reducing mortality from breast cancer</article-title>. <source>Jama</source>. <year>1971</year>;<volume>215</volume>(<issue>11</issue>):<fpage>1777</fpage>–<lpage>1785</lpage>. <?supplied-pmid 5107709?><pub-id pub-id-type="pmid">5107709</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>M</given-names></name>, <name><surname>Alexander</surname><given-names>F</given-names></name>, <name><surname>Anderson</surname><given-names>T</given-names></name>, <name><surname>Forrest</surname><given-names>A</given-names></name>, <name><surname>Hepburn</surname><given-names>W</given-names></name>, <name><surname>Huggins</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>The Edinburgh randomised trial of screening for breast cancer: description of method</article-title>. <source>British journal of cancer</source>. <year>1984</year>;<volume>50</volume>(<issue>1</issue>):<fpage>1</fpage><pub-id pub-id-type="doi">10.1038/bjc.1984.132</pub-id><?supplied-pmid 6743506?><pub-id pub-id-type="pmid">6743506</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Alexander</surname><given-names>F</given-names></name>, <name><surname>Anderson</surname><given-names>T</given-names></name>, <name><surname>Brown</surname><given-names>H</given-names></name>, <name><surname>Forrest</surname><given-names>A</given-names></name>, <name><surname>Hepburn</surname><given-names>W</given-names></name>, <name><surname>Kirkpatrick</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>The Edinburgh randomised trial of breast cancer screening: results after 10 years of follow-up</article-title>. <source>British journal of cancer</source>. <year>1994</year>;<volume>70</volume>(<issue>3</issue>):<fpage>542</fpage><pub-id pub-id-type="doi">10.1038/bjc.1994.342</pub-id><?supplied-pmid 8080744?><pub-id pub-id-type="pmid">8080744</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>AB</given-names></name>, <name><surname>Wall</surname><given-names>C</given-names></name>, <name><surname>Baines</surname><given-names>CJ</given-names></name>, <name><surname>Sun</surname><given-names>P</given-names></name>, <name><surname>To</surname><given-names>T</given-names></name>, <name><surname>Narod</surname><given-names>SA</given-names></name>. <article-title>Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial</article-title>. <source>Bmj</source>. <year>2014</year>;<volume>348</volume>:<fpage>g366</fpage><pub-id pub-id-type="doi">10.1136/bmj.g366</pub-id><?supplied-pmid 24519768?><pub-id pub-id-type="pmid">24519768</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Duffy</surname><given-names>SW</given-names></name>, <name><surname>Tabar</surname><given-names>L</given-names></name>, <name><surname>Vitak</surname><given-names>B</given-names></name>, <name><surname>Yen</surname><given-names>M</given-names></name>, <name><surname>Warwick</surname><given-names>J</given-names></name>, <name><surname>Smith</surname><given-names>R</given-names></name>, <etal>et al</etal><article-title>The Swedish Two-County Trial of mammographic screening: cluster randomisation and end point evaluation</article-title>. <source>Annals of Oncology</source>. <year>2003</year>;<volume>14</volume>(<issue>8</issue>):<fpage>1196</fpage>–<lpage>1198</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdg322</pub-id>
<?supplied-pmid 12881376?><pub-id pub-id-type="pmid">12881376</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Tabár</surname><given-names>L</given-names></name>, <name><surname>Vitak</surname><given-names>B</given-names></name>, <name><surname>Chen</surname><given-names>THH</given-names></name>, <name><surname>Yen</surname><given-names>AMF</given-names></name>, <name><surname>Cohen</surname><given-names>A</given-names></name>, <name><surname>Tot</surname><given-names>T</given-names></name>, <etal>et al</etal><article-title>Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades</article-title>. <source>Radiology</source>. <year>2011</year>;<volume>260</volume>(<issue>3</issue>):<fpage>658</fpage>–<lpage>663</lpage>. <pub-id pub-id-type="doi">10.1148/radiol.11110469</pub-id>
<?supplied-pmid 21712474?><pub-id pub-id-type="pmid">21712474</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>RA</given-names></name>, <name><surname>Duffy</surname><given-names>SW</given-names></name>, <name><surname>Gabe</surname><given-names>R</given-names></name>, <name><surname>Tabar</surname><given-names>L</given-names></name>, <name><surname>Yen</surname><given-names>AM</given-names></name>, <name><surname>Chen</surname><given-names>TH</given-names></name>. <article-title>The randomized trials of breast cancer screening: what have we learned?</article-title><source>Radiologic Clinics</source>. <year>2004</year>;<volume>42</volume>(<issue>5</issue>):<fpage>793</fpage>–<lpage>806</lpage>. <?supplied-pmid 15337416?><pub-id pub-id-type="pmid">15337416</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Bleyer</surname><given-names>A</given-names></name>, <name><surname>Welch</surname><given-names>HG</given-names></name>. <article-title>Effect of three decades of screening mammography on breast-cancer incidence</article-title>. <source>New England Journal of Medicine</source>. <year>2012</year>;<volume>367</volume>(<issue>21</issue>):<fpage>1998</fpage>–<lpage>2005</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1206809</pub-id>
<?supplied-pmid 23171096?><pub-id pub-id-type="pmid">23171096</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Welch</surname><given-names>HG</given-names></name>, <name><surname>Prorok</surname><given-names>PC</given-names></name>, <name><surname>O’Malley</surname><given-names>AJ</given-names></name>, <name><surname>Kramer</surname><given-names>BS</given-names></name>. <article-title>Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness</article-title>. <source>New England Journal of Medicine</source>. <year>2016</year>;<volume>375</volume>(<issue>15</issue>):<fpage>1438</fpage>–<lpage>1447</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1600249</pub-id>
<?supplied-pmid 27732805?><pub-id pub-id-type="pmid">27732805</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Welch</surname><given-names>HG</given-names></name>, <name><surname>Fisher</surname><given-names>ES</given-names></name>. <article-title>Income and cancer overdiagnosis–when too much care is harmful</article-title>. <source>New England Journal of Medicine</source>. <year>2017</year>;<volume>376</volume>(<issue>23</issue>):<fpage>2208</fpage>–<lpage>2209</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMp1615069</pub-id>
<?supplied-pmid 28591536?><pub-id pub-id-type="pmid">28591536</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Esserman</surname><given-names>LJ</given-names></name>. <article-title>The WISDOM Study: breaking the deadlock in the breast cancer screening debate</article-title>. <source>NPJ breast cancer</source>. <year>2017</year>;<volume>3</volume>(<issue>1</issue>):<fpage>34</fpage><pub-id pub-id-type="doi">10.1038/s41523-017-0035-5</pub-id><?supplied-pmid 28944288?><pub-id pub-id-type="pmid">28944288</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Tsunematsu</surname><given-names>M</given-names></name>, <name><surname>Kakehashi</surname><given-names>M</given-names></name>. <article-title>An analysis of mass screening strategies using a mathematical model: comparison of breast cancer screening in Japan and the United States</article-title>. <source>Journal of epidemiology</source>. <year>2015</year>;<volume>25</volume>(<issue>2</issue>):<fpage>162</fpage>–<lpage>171</lpage>. <pub-id pub-id-type="doi">10.2188/jea.JE20140047</pub-id>
<?supplied-pmid 25483105?><pub-id pub-id-type="pmid">25483105</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Molani</surname><given-names>S</given-names></name>, <name><surname>Madadi</surname><given-names>M</given-names></name>, <name><surname>Wilkes</surname><given-names>W</given-names></name>. <article-title>A partially observable Markov chain framework to estimate overdiagnosis risk in breast cancer screening: Incorporating uncertainty in patients adherence behaviors</article-title>. <source>Omega</source>. <year>2019</year>;<volume>89</volume>:<fpage>40</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.omega.2018.09.009</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Gunsoy</surname><given-names>N</given-names></name>, <name><surname>Garcia-Closas</surname><given-names>M</given-names></name>, <name><surname>Moss</surname><given-names>S</given-names></name>. <article-title>Estimating breast cancer mortality reduction and overdiagnosis due to screening for different strategies in the United Kingdom</article-title>. <source>British journal of cancer</source>. <year>2014</year>;<volume>110</volume>(<issue>10</issue>):<fpage>2412</fpage><pub-id pub-id-type="doi">10.1038/bjc.2014.206</pub-id><?supplied-pmid 24762956?><pub-id pub-id-type="pmid">24762956</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Brock</surname><given-names>G</given-names></name>, <name><surname>Wu</surname><given-names>D</given-names></name>. <article-title>Estimating key parameters in periodic breast cancer screening-application to the Canadian National Breast Screening Study data</article-title>. <source>Cancer epidemiology</source>. <year>2010</year>;<volume>34</volume>(<issue>4</issue>):<fpage>429</fpage>–<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1016/j.canep.2010.04.001</pub-id>
<?supplied-pmid 20434974?><pub-id pub-id-type="pmid">20434974</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Taghipour</surname><given-names>S</given-names></name>, <name><surname>Banjevic</surname><given-names>D</given-names></name>, <name><surname>Miller</surname><given-names>A</given-names></name>, <name><surname>Montgomery</surname><given-names>N</given-names></name>, <name><surname>Jardine</surname><given-names>A</given-names></name>, <name><surname>Harvey</surname><given-names>B</given-names></name>. <article-title>Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study</article-title>. <source>British journal of cancer</source>. <year>2013</year>;<volume>108</volume>(<issue>3</issue>):<fpage>542</fpage><pub-id pub-id-type="doi">10.1038/bjc.2012.596</pub-id><?supplied-pmid 23322203?><pub-id pub-id-type="pmid">23322203</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>De Gelder</surname><given-names>R</given-names></name>, <name><surname>Heijnsdijk</surname><given-names>EA</given-names></name>, <name><surname>Van Ravesteyn</surname><given-names>NT</given-names></name>, <name><surname>Fracheboud</surname><given-names>J</given-names></name>, <name><surname>Draisma</surname><given-names>G</given-names></name>, <name><surname>De Koning</surname><given-names>HJ</given-names></name>. <article-title>Interpreting overdiagnosis estimates in population-based mammography screening</article-title>. <source>Epidemiologic reviews</source>. <year>2011</year>;<volume>33</volume>(<issue>1</issue>):<fpage>111</fpage>–<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1093/epirev/mxr009</pub-id>
<?supplied-pmid 21709144?><pub-id pub-id-type="pmid">21709144</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Shaevitch</surname><given-names>D</given-names></name>, <name><surname>Taghipour</surname><given-names>S</given-names></name>, <name><surname>Miller</surname><given-names>AB</given-names></name>, <name><surname>Montgomery</surname><given-names>N</given-names></name>, <name><surname>Harvey</surname><given-names>B</given-names></name>, <etal>et al</etal><article-title>Tumor size distribution of invasive breast cancers and the sensitivity of screening methods in the Canadian National Breast Screening Study</article-title>. <source>Journal of cancer research and therapeutics</source>. <year>2017</year>;<volume>13</volume>(<issue>3</issue>):<fpage>562</fpage><?supplied-pmid 28862227?><pub-id pub-id-type="pmid">28862227</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Gaudette</surname><given-names>LA</given-names></name>, <name><surname>Silberberger</surname><given-names>C</given-names></name>, <name><surname>Altmayer</surname><given-names>CA</given-names></name>, <name><surname>Gao</surname><given-names>RN</given-names></name>. <article-title>Trends in breast cancer incidence and mortality</article-title>. <source>Health Reports-Statistics Canada</source>. <year>1996</year>;<volume>8</volume>:<fpage>29</fpage>–<lpage>38</lpage>.</mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref021">
                <label>21</label>
                <mixed-citation publication-type="other">Statistics Canada. Table 13-10-0710-01 Deaths and mortality rates, by age group. 1991;.</mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Norton</surname><given-names>L</given-names></name>. <article-title>A Gompertzian model of human breast cancer growth</article-title>. <source>Cancer research</source>. <year>1988</year>;<volume>48</volume>(<issue>24 Part 1</issue>):<fpage>7067</fpage>–<lpage>7071</lpage>. <?supplied-pmid 3191483?><pub-id pub-id-type="pmid">3191483</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Spratt</surname><given-names>JA</given-names></name>, <name><surname>Von Fournier</surname><given-names>D</given-names></name>, <name><surname>Spratt</surname><given-names>JS</given-names></name>, <name><surname>Weber</surname><given-names>EE</given-names></name>. <article-title>Decelerating growth and human breast cancer</article-title>. <source>Cancer</source>. <year>1993</year>;<volume>71</volume>(<issue>6</issue>):<fpage>2013</fpage>–<lpage>2019</lpage>. <?supplied-pmid 8443753?><pub-id pub-id-type="pmid">8443753</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Weedon-Fekjær</surname><given-names>H</given-names></name>, <name><surname>Tretli</surname><given-names>S</given-names></name>, <name><surname>Aalen</surname><given-names>OO</given-names></name>. <article-title>Estimating screening test sensitivity and tumour progression using tumour size and time since previous screening</article-title>. <source>Statistical methods in medical research</source>. <year>2010</year>;<volume>19</volume>(<issue>5</issue>):<fpage>507</fpage>–<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1177/0962280209359860</pub-id>
<?supplied-pmid 20356856?><pub-id pub-id-type="pmid">20356856</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Michaelson</surname><given-names>JS</given-names></name>, <name><surname>Chen</surname><given-names>LL</given-names></name>, <name><surname>Silverstein</surname><given-names>MJ</given-names></name>, <name><surname>Mihm</surname><given-names>MC</given-names><suffix>Jr</suffix></name>, <name><surname>Sober</surname><given-names>AJ</given-names></name>, <name><surname>Tanabe</surname><given-names>KK</given-names></name>, <etal>et al</etal><article-title>How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death</article-title>. <source>Cancer: Interdisciplinary International Journal of the American Cancer Society</source>. <year>2009</year>;<volume>115</volume>(<issue>21</issue>):<fpage>5095</fpage>–<lpage>5107</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.24592</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Michaelson</surname><given-names>JS</given-names></name>, <name><surname>Silverstein</surname><given-names>M</given-names></name>, <name><surname>Wyatt</surname><given-names>J</given-names></name>, <name><surname>Weber</surname><given-names>G</given-names></name>, <name><surname>Moore</surname><given-names>R</given-names></name>, <name><surname>Halpern</surname><given-names>E</given-names></name>, <etal>et al</etal><article-title>Predicting the survival of patients with breast carcinoma using tumor size</article-title>. <source>Cancer</source>. <year>2002</year>;<volume>95</volume>(<issue>4</issue>):<fpage>713</fpage>–<lpage>723</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.10742</pub-id>
<?supplied-pmid 12209713?><pub-id pub-id-type="pmid">12209713</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Wahed</surname><given-names>AS</given-names></name>, <name><surname>Luong</surname><given-names>TM</given-names></name>, <name><surname>Jeong</surname><given-names>JH</given-names></name>. <article-title>A new generalization of Weibull distribution with application to a breast cancer data set</article-title>. <source>Statistics in medicine</source>. <year>2009</year>;<volume>28</volume>(<issue>16</issue>):<fpage>2077</fpage>–<lpage>2094</lpage>. <pub-id pub-id-type="doi">10.1002/sim.3598</pub-id>
<?supplied-pmid 19424958?><pub-id pub-id-type="pmid">19424958</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Weedon-Fekjær</surname><given-names>H</given-names></name>, <name><surname>Lindqvist</surname><given-names>BH</given-names></name>, <name><surname>Vatten</surname><given-names>LJ</given-names></name>, <name><surname>Aalen</surname><given-names>OO</given-names></name>, <name><surname>Tretli</surname><given-names>S</given-names></name>. <article-title>Breast cancer tumor growth estimated through mammography screening data</article-title>. <source>Breast Cancer Research</source>. <year>2008</year>;<volume>10</volume>(<issue>3</issue>):<fpage>R41</fpage><pub-id pub-id-type="doi">10.1186/bcr2092</pub-id><?supplied-pmid 18466608?><pub-id pub-id-type="pmid">18466608</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Thanh</surname><given-names>VH</given-names></name>, <name><surname>Priami</surname><given-names>C</given-names></name>. <article-title>Simulation of biochemical reactions with time-dependent rates by the rejection-based algorithm</article-title>. <source>The Journal of chemical physics</source>. <year>2015</year>;<volume>143</volume>(<issue>5</issue>):08B601_1. <pub-id pub-id-type="doi">10.1063/1.4927916</pub-id><?supplied-pmid 26254639?><pub-id pub-id-type="pmid">26254639</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref030">
                <label>30</label>
                <mixed-citation publication-type="other">Therneau TM. A Package for Survival Analysis in S; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=survival">https://CRAN.R-project.org/package=survival</ext-link></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Madadi</surname><given-names>M</given-names></name>, <name><surname>Heydari</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>S</given-names></name>, <name><surname>Pohl</surname><given-names>E</given-names></name>, <name><surname>Rainwater</surname><given-names>C</given-names></name>, <name><surname>Williams</surname><given-names>DL</given-names></name>. <article-title>Analyzing overdiagnosis risk in cancer screening: A case of screening mammography for breast cancer</article-title>. <source>IISE Transactions on Healthcare Systems Engineering</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>2</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1080/24725579.2017.1396512</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Duffy</surname><given-names>SW</given-names></name>, <name><surname>Agbaje</surname><given-names>O</given-names></name>, <name><surname>Tabar</surname><given-names>L</given-names></name>, <name><surname>Vitak</surname><given-names>B</given-names></name>, <name><surname>Bjurstam</surname><given-names>N</given-names></name>, <name><surname>Björneld</surname><given-names>L</given-names></name>, <etal>et al</etal><article-title>Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer</article-title>. <source>Breast Cancer Research</source>. <year>2005</year>;<volume>7</volume>(<issue>6</issue>):<fpage>258</fpage><pub-id pub-id-type="doi">10.1186/bcr1354</pub-id><?supplied-pmid 16457701?><pub-id pub-id-type="pmid">16457701</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Kurian</surname><given-names>AW</given-names></name>, <name><surname>Gong</surname><given-names>GD</given-names></name>, <name><surname>John</surname><given-names>EM</given-names></name>, <name><surname>Johnston</surname><given-names>DA</given-names></name>, <name><surname>Felberg</surname><given-names>A</given-names></name>, <name><surname>West</surname><given-names>DW</given-names></name>, <etal>et al</etal><article-title>Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry</article-title>. <source>Journal of Clinical Oncology</source>. <year>2011</year>;<volume>29</volume>(<issue>34</issue>):<fpage>4505</fpage><pub-id pub-id-type="doi">10.1200/JCO.2010.34.4440</pub-id><?supplied-pmid 22042950?><pub-id pub-id-type="pmid">22042950</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1008036.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>A</given-names></name>, <name><surname>Howe</surname><given-names>G</given-names></name>, <name><surname>Wall</surname><given-names>C</given-names></name>. <article-title>The national study of breast cancer screening</article-title>. <source>Clin Invest Med</source>. <year>1981</year>;<volume>4</volume>:<fpage>227</fpage>–<lpage>258</lpage>. <?supplied-pmid 6802546?><pub-id pub-id-type="pmid">6802546</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
